ALS Clinical Trial
Official title:
Digital Tools for Assessment of Motor Functions and Falls in ALS
This is a 48-week single arm study that incorporates digital tools for assessing motor function as part of an ALS telemonitoring program. During the study, neck- and wrist-worn "activity sensors" (PAMSys, BioSensics, Newton, MA) that will be worn by subjects while performing tasks of daily living. Subjects will also complete a motor, speech, and handwriting assessment during site visits. Subjects will complete a digital home assessments of speech, handwriting, and pattern tracing tasks throughout the study, and report any falls which occur on the study tablet. The investigators will explore whether functional changes are sensitive to self-reported changes on the ALS Functional Rating Scale - Revised (ALFRS-R) over the length of the study.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | September 30, 2025 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria 1. Diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria [Brooks2000], primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA). 2. 18 years of age or older; 3. ALSFRS-R walking sub-score of either 4 (normal gait), 3 (early ambulation difficulties), or 2 (walking with assistance); 4. Fluent in written and spoken English. Exclusion Criteria 1. Neurological or orthopedic problems independent of their inclusionary diagnosis that affects their gait; 2. Pregnant or nursing woman; 3. Prisoner or institutionalized individuals; 4. Have any clinically relevant medical history of other disease or diseases that, in the opinion of the research team, exclude the subject from participation (including severe cognitive dysfunction). |
Country | Name | City | State |
---|---|---|---|
United States | Milton S. Hershey Medical Center | Hershey | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Milton S. Hershey Medical Center | BioSensics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Physical Activity at 10 months | Changes in physical activity from baseline to 10 months will be assessed. Physical activity will be quantified by measuring number of taken steps per day and will be measured using a validated wearable sensor named PAMSys. Monitoring of physical activity will be done during 72 hours at baseline and 72 hours at 10 months. | baseline and visit 4 (an average of 10 months) | |
Secondary | Change from baseline in total lower limb muscle strength at end of study | Strength testing is performed by the attending neurologist at clinical appointments. Bilateral hip flexion, knee extension and flexion, and foot dorsiflexion strength will be documented according to Medical Research Council (MRC) grade 0 (no power) to 5 (normal power). Total score for bilateral muscle groups ranges from 0 to 40. Change in total lower limb strength score over study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in total upper limb muscle strength at end of study | Strength testing is performed by the attending neurologist at clinical appointments. Bilateral deltoids, biceps, triceps, wrist extension, and interossei strength will be documented according to Medical Research Council (MRC) grade 0 (no power) to 5 (normal power). Total score for bilateral muscle groups ranges from 0 to 50. Change in total upper limb strength score over study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in total upper limb reflexes at end of study | Reflex testing is performed by the attending neurologist at clinical appointments. Bilateral biceps, triceps, and brachioradialis reflexes will be documented according to Modified Ashworth Scale grade 0 (no tone increase) to 4 (limb rigid). Total score for bilateral muscle groups ranges from 0 to 24. Change in total upper limb reflexes over study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in total lower limb reflexes at end of study | Reflex testing is performed by the attending neurologist at clinical appointments. Bilateral patellar and achilles reflexes will be documented according to Modified Ashworth Scale grade 0 (no tone increase) to 4 (limb rigid). Total score for bilateral muscle groups ranges from 0 to 16. Change in total lower limb reflexes over study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in Forced Vital Capacity at end of study | Forced vital capacity (FVC) is collected at clinical appointments. FVC is expressed as a percentage (%) of predicted volume against an age, height, and ethnicity matched standard. Change in FVC over this time period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in total ALSFRS-R at end of study | ALS Functional Rating Scale-Revised (ALSFRS-R) measures function in 12 domains. The total score ranges from 48 (normal function) to 0 (no function). Change in total score over this time period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in ALSFRS-R gross motor subscore at end of study | ALS Functional Rating Scale-Revised (ALSFRS-R) gross motor subscore measures function in 3 domains. The total subscore ranges from 12 (normal function) to 0 (no function). Change in total subscore over this time period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in ALSFRS-R fine motor subscore at end of study | ALS Functional Rating Scale-Revised (ALSFRS-R) fine motor subscore measures function in 3 domains. The total subscore ranges from 12 (normal function) to 0 (no function). Change in total subscore over this time period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in "Falls Efficacy Scale - International" total score at end of study | The Falls Efficacy Scale - International (FES-I) is collected at study visits. The total score ranges from 64 (high concern about falling) to 0 (no concern about falling). Change in total score over this time period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in "Fatigue Severity Scale" total score at end of study | The Fatigue Severity Scale is collected at study visits. The total score ranges from 63 (high fatigue) to 9 (low fatigue). Change in total score over this time period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in "Neurological Fatigue Index - Motor Neuron Disease" weakness subscale at end of study | The Neurological Fatigue Index - Motor Neuron Disease is collected at study visits. The weakness subscale total score ranges from 21 (high fatigue) to 7 (low fatigue). Change in total score over this time period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in "Neurological Fatigue Index - Motor Neuron Disease" energy subscale at end of study | The Neurological Fatigue Index - Motor Neuron Disease is collected at study visits. The energy subscale total score ranges from 18 (high fatigue) to 6 (low fatigue). Change in total score over this time period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in speaking rate at end of study | Subjects will complete the audio recording of a standard reading passage every two weeks. The speaking rate will be calculated from this audio, and the change in speaking rate over the study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in 3-meter Timed-Up-and-Go at end of study | 3-meter timed-up-and-go task is recorded at study visits. The best time of three trials is recorded. Change in best time over the study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Change from baseline in 10 meter walk at end of study | A 10-meter walk task is recorded at study visits. The best time of three trials is recorded. Change in best time over the study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Handwriting Assessment: Change from baseline in handwriting speed at end of study | As part of the Handwriting Assessment Battery completed at study visits, subjects will copy a standard sentence from a prompt in the booklet. The change in writing speed for this copying task over the study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Handwriting Assessment: Change from baseline in legibility at end of study | As part of the Handwriting Assessment Battery (HAB) completed at study visits, subjects will print the alphabet in upper and lowercase, as well as the numbers 1-12. Legibility will be determined as the percent of individual characters rated as legible according to the HAB handbook. The change in character legibility over the study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Digital Handwriting Assessment: Change from baseline in handwriting speed at end of study | As part of the Digital Handwriting Assessment performed every two weeks on the study tablet, subjects will copy a standard sentence from a prompt on the tablet. The change in writing speed for this copying task over the study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Digital Handwriting Assessment: Change from baseline in legibility at end of study | As part of the Digital Handwriting Assessment performed every two weeks on the study tablet, subjects will print the alphabet in upper and lowercase, as well as the numbers 1-12. Legibility will be determined as the percent of individual characters rated as legible according to the HAB handbook. The change in character legibility over the study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Digital Handwriting Assessment: Change from baseline in spiral tracing speed at end of study | As part of the Digital Handwriting Assessment performed every two weeks on the study tablet, subjects will be timed as they trace the outline of a spiral. The change in time to complete the tracing over the study period will be calculated. | baseline and end of study (an average of 1 year) | |
Secondary | Fall Event Detections | Fall events (falls and near-falls) detected by the sensor are registered on the study tablet. The total number of fall events registered over the course of the study is a secondary outcome. | end of study (an average of 1 year) | |
Secondary | Fall Event Reports | Subjects enter fall event reports in the study tablet. The total number of reports reported over the course of the study is a secondary outcome | end of study (an average of 1 year) | |
Secondary | Adherence: Tablet Assessments | Total number of assessments (handwriting, speech, and pattern tracing) completed on the tablet over the study period. | end of study (an average of 1 year) | |
Secondary | Adherence: Fall Sensor | Total number of hours registered with wearing the fall sensor over the study period. | end of study (an average of 1 year) | |
Secondary | Adherence: Activity Sensor | Total number of hours registered with wearing the activity sensors over the study period. | end of study (an average of 1 year) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Completed |
NCT02405182 -
MRI Biomarkers in ALS
|
||
Completed |
NCT00696332 -
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT03865420 -
Amyotrophic Lateral Sclerosis (ALS) Families Project
|
||
Terminated |
NCT04054141 -
rTMS in Treatment of Spasticity
|
N/A | |
Recruiting |
NCT03272503 -
A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT05568615 -
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
|
Phase 3 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Active, not recruiting |
NCT04259255 -
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
|
||
Recruiting |
NCT02495571 -
Assessment of Voluntary and Reflex Cough in Patients With ALS
|
N/A | |
Completed |
NCT02525471 -
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 1 | |
Recruiting |
NCT05031351 -
NF-κB Inhibition in Amyotrophic Lateral Sclerosis
|
Phase 2 | |
Active, not recruiting |
NCT05581771 -
Factors Associated With Success of NIPPV in ALS Patients
|
||
Active, not recruiting |
NCT03268603 -
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT06005506 -
National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chronically Frail Patients Who Share Alterations in Intestinal Function.
|
N/A | |
Recruiting |
NCT04138095 -
Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care
|
N/A | |
Recruiting |
NCT03698149 -
ECoG BMI for Motor and Speech Control
|
N/A | |
Not yet recruiting |
NCT05621213 -
Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation
|
N/A | |
Terminated |
NCT03373981 -
Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS
|
N/A | |
Completed |
NCT04165850 -
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
|
Phase 2 |